Several anticancer tyrosine kinase inhibitors and the ongoing clinical trials targeting HGF and c-Met receptor are summarised by Rothenberger NJ et al. [196] Cirzotinib (PF-2341066) is a tyrosine kinase inhibitor that when used in combination with docetaxel and cisplatin showed synergistic antitumor effects in HNSCC CSCs in a patient-derived xenograft (PDX) model [197,199]. This evidence concerns the gene HGF and head and neck squamous cell carcinoma.